课题基金 / 基金详情

AVONEX (IFN B1A) IN SUBJECTS AT HIGH RISK FOR DEVELOPMENT OF MULTIPLE SCLEROSIS

AVONEX (IFN B1A) IN SUBJECTS AT HIGH RISK FOR DEVELOPMENT OF MULTIPLE SCLEROSIS
AVONEX (IFN B1A) 用于多发性硬化症高风险受试者
批准号：
6281678
负责人：
STALEY armstrong BROD
金额：
$1.36万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6281678
关键词：
clinical research disease /disorder prevention /control drug administration routes human subject human therapy evaluation immunopathology chemotherapy immunotherapy interferon beta longitudinal human study multiple sclerosis nervous system disorder chemotherapy placebos

项目摘要

项目成果

STALEY armstrong BROD的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
AVONEX, a recombinant human interferon-beta product, is an antiviral protein produced by fibroblasts after induction by viral infection. This randomized, double-blinded, placebo-controlled study will determine if AVONEX is beneficial in delaying the onset of clinically definite multiple sclerosis in subjects who have experienced a first and recent onset of a demyelinating event, and who are at high risk for multiple sclerosis. A total of 380 subjects will be treated with IM injections of AVONEX or placebo weekly for up to three years. Six patients were enrolled at this center, and there will be no more recruiting. Followup of these patients will continue.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IFNA: PROLONGATION OR PERMANENCE OF THE "HONEYMOON" PHASE IN DIABETES MELLITUS
PREVENTION OF COGNITIVE DECLINE IN ALZHEIMER'S DISEASE VIA INGESTED IFN-ALPHA
PROTEIN BIOMARKERS OF IFN-ALPHA IN MS
INGESTED IFN-A: PROLONGATION OR PERMANENCE OF THE "HONEYMOON" PHASE IN DIABETES